Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    The press-release listing adds updates on Regeneron’s third-quarter 2026 results, an expanded BARDA agreement for Inmazeb supply, and longer-term Libtayo survival data. Several earlier investor, clinical-trial, and award announcements no longer appear in the listing.
    Difference
    6%
    Check dated 2026-10-31T13:24:58.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The press-release listing now features updates on Libtayo's recommended EU approval for an updated dosing regimen and Pasatru's OPTIMA trial extension results. Older announcements about second-quarter 2026 results and the related earnings call are no longer listed.
    Difference
    6%
    Check dated 2026-10-17T14:35:21.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    A new October 6, 2026 press release highlights Regeneron’s advances in cancer care and related complications at ESMO 2026. The June 22, 2026 release about FDA and EMA review of cemdisiran submissions is no longer listed.
    Difference
    2%
    Check dated 2026-10-10T14:45:48.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Three October 1, 2026 releases announce durable responses in an ovarian cancer study, muscle-loss prevention findings from the COURAGE trial, and an expanded Regeneron–Sanofi immunology alliance. Older releases from May and June 2026 are no longer listed.
    Difference
    6%
    Check dated 2026-10-03T14:34:51.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Added a new entry for Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026 (dated September 24, 2026 4:05 PM EDT). Removed the Lynozyfic® (linvoseltamab) Monotherapy press release (dated May 21, 2026 5:01 PM EDT) from the listing.
    Difference
    2%
    Check dated 2026-09-26T17:19:30.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Two new press releases were added to the page—one announcing investor conference presentations and another detailing Pasatru’s FDA-approved trial results—highlighting fresh investor-focused news. Older May 2026 entries were removed, reflecting archival cleanup of outdated items.
    Difference
    6%
    Check dated 2026-08-22T20:43:25.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.